港股異動 | 加科思-B(1167.HK)上市次日續漲超5%
格隆匯12月22日丨加科思-B(1167.HK)今日續漲,現報15.16港元,漲5.13%,暫成交7080萬港元,最新總市值115億港元,該股昨日於港交所上市,發行價14港元。公司是一家臨牀階段製藥企業,專注於創新腫瘤療法的自主發現和開發。此次上市全球發售9647.61萬股,其中香港發售4824萬股,國際發售4823.61萬股,每手300股,香港公開發售獲299.59倍認購,淨籌12.631億港元,當中88%擬主要用於相關產品的臨牀開發及商業化。格隆匯平台昨日發佈分析文章《加科思-B(1167.HK)登陸港交所,創新研發打開商業化前景》,可點擊下列鏈接瞭解。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.